1. Russian Federation Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Farmsintez

Farmsintez

MMOEX:LIFE
1.67
RUB
+0.01
(+0.30%)
149.25P/E
Farmsintez
MOEX:LIFE
(Russian Exchange)

Recent

price

1.67

P/E

ratio

149.25

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
RUB
1.38
1.44
1.83
- -
- -
- -
2.27
2.65
2.18
4.36
2.3
0.94
0.97
1.23
1.46
1.26
0.32
Revenue per Share
0.14
0.02
0.11
- -
- -
- -
-1.37
-1.43
-2.34
-4.23
-3.57
0.2
-6.02
-1.74
-2.32
-0.69
0.09
Basic EPS, GAAP
- -
-0.03
-0.04
- -
- -
- -
-4.43
-6.46
-1.44
-2.81
-0.59
- -
-0.28
-0.81
-0.21
-0.02
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.11
2.13
2.17
- -
- -
- -
13.8
15.27
14.04
11.25
15.94
16.22
4.53
3.37
1.15
0.4
15.27
Book Value per Share
2.09
2.11
2.15
- -
- -
- -
11.16
13.05
11.81
9.38
14.63
14.86
3.34
1.98
-0.18
-0.91
13.05
Tangible Book Value per Share
125
125
125
- -
- -
- -
108
143
152
152
276
301
301
301
301
301
125
Basic Weighted Avg Shares
173
180
228
275
412
- -
245
378
331
661
635
282
291
372
438
380
40
Sales/Revenue/Turnover
18.75
11.64
7.18
15.27
0.73
- -
-77.52
-75.62
-165.28
-88.07
-41.89
25.56
-48.83
-11.14
-38.59
-35.91
-43.45
Operating Margin (%)
- -
- -
- -
- -
- -
- -
23
36
32
72
51
- -
26
44
32
28
- -
Depreciation Expense
17
2
14
19
14
- -
-147
-205
-355
-642
-987
60
-1,812
-525
-698
-207
11
Net Income, GAAP
31.81
62.17
- -
29.63
50
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
24.17
Effective Tax Rate (%)
9.78
1.18
6.15
6.91
3.4
- -
-60.13
-54.21
-107.06
-97.06
-155.35
21.21
-622.45
-141.21
-159.14
-54.65
26.75
Profit Margin (%)
23
43
51
77
470
187
675
959
677
-4,397
-1,005
-811
-456
-560
-787
-977
959
Working Capital
- -
- -
- -
- -
- -
2
4
6
2
- -
54
- -
141
13
87
42
6
LT Debt
264
266
270
290
827
696
1,723
2,317
2,130
2,010
4,822
4,882
1,364
1,014
345
121
2,317
Total Equity
- -
2.78
- -
9.86
0.26
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
0.97
- -
6.77
2.76
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.3
Return on Capital (%)
- -
0.8
5.24
6.78
2.51
- -
-12.18
-10.14
-15.96
-33.46
-30.35
1.23
-58.01
-44.13
-102.63
-88.98
1.88
Return on Common Equity (%)

Capital Structure

RUB

•

in mil. unless spec.
Sep'14
Dec'14
ST Debt
- -
29
LT Borrowings
- -
- -
LT Finance Leases
- -
6
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
152
152
Market Capitalization
2,124
1,927

Working Capital

RUB

•

in mil. unless spec.
Sep'14
Dec'14
Total Current Assets
1,146
1,181
Cash, Cash Equivalents & STI
202
179
Accounts Receivable, Net
716
270
Inventories
182
155
Total Current Liabilities
198
222
Payables & Accruals
- -
- -
ST Debt
- -
29
Deferred Revenue
- -
- -

Growth Rates

RUB

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.08%
-45.47%
-64.93%
Free Cash Flow
- -
- -
-89.17%
Net Income, GAAP
- -
-669.22%
-70.25%
Sales/Revenue/Turnover
- -
-4.02%
-13.38%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

RUB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
438
2022
- -
- -
- -
- -
380
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

RUB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-2.32
2022
- -
- -
- -
- -
-0.69
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

RUB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
PJSC Pharmsynthez (MOEX: LIFE) operates as a leading Russian pharmaceutical group specializing in the research, development, production, and sales of innovative and generic medicines targeting socially significant diseases including tuberculosis, HIV/AIDS, oncology, hepatitis, diabetes, blood disorders, and immunodeficiencies; its core offerings encompass over 300 drug types and more than 60 pharmaceutical substances across all dosage forms such as tablets, capsules, granules, infusion solutions, sterile powders, and injectables, with key brands including Neovir, Segidrin, Fenasid, and Penkrofton, alongside active pharmaceutical ingredients (APIs), hospital antibiotics, antiretrovirals, and antineoplastics produced at five high-technology GMP-compliant factories in Irkutsk, St. Petersburg, Ussuriysk, Bratsk, and Tyumen. The company maintains a robust research center focused on original drug technologies, organ-specific delivery systems, and import-substitution generics, serving public hospital procurements where its Russian-made products hold a 72.8% volume share, while exporting to CIS countries and collaborating with North American, Canadian, and European partners on chemical compounds and custom API synthesis. Founded in 1996 with headquarters in Irkutsk, Russia, and additional operations in St. Petersburg, PJSC Pharmsynthez drives annual production exceeding 87 million packs through advanced facilities equipped by global manufacturers. Recent developments include a RUB 800 million put option agreement with LDA Capital in 2024 to fund pioneering projects over 36 months, such as launching original drugs like Epolong for domestic markets, expanding API production, and introducing vaccines including Xemys for multiple sclerosis, Sci-B-Vac for hepatitis B prevention, and COVID-19 treatments; in 2025, the company announced plans to launch Russia's first innovative medication for chronic myeloid leukemia (CML) blood cancer, signed a partnership with Skolkovo Foundation at SPIEF-2025, participated as general partner in the IPhEB 2025 exhibition, showcased innovations at CPHI & PMEC China, and saw founder Vikram Punia recognized in Forbes' World Billionaires Ranking.